Computing-enabled R&D shop Schrödinger will use its $110 million haul to advance its nascent pipeline of wholly owned drugs.
There are thousands of clinical trials ongoing around the world, but only a small percentage of patients participate. Icon is hoping to change that.
Ginkgo Bioworks is buying Warp Drive Bio’s genome mining team, tech and database, eyeing the platform for use in next-gen antibiotics.
To make clinical trials more affordable and lead to the results needed for approval, MarkLogic has set up a new hub designed to do just that.
Janssen has become the latest Big Pharma to delve deeper into AI's potential to boost the number of successful drugs coming through the pipeline.
Adimab is continuing a dealmaking streak with three more deal expansions, with Novartis, Regeneron and Takeda.
WuXi AppTec’s CRO arm WuXi Clinical will subsume Pharmapace into its business as the China giant looks to up its trial services in biometrics.
AI in drug development is among the hottest buzzwords in biopharma right now, but real progress is hampered by lack of expertise and access.
Charles River Labs has been hit by “a highly sophisticated, well-resourced intruder” who hacked into 1% of its clients' data.
The Michael J. Fox Foundation and 23andMe are launching a network aimed at combining the patient voice and genetic data from Parkinson’s patients.
